EASL clinical practice guidelines for HFE hemochromatosis

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 3-22

  European Association for the Study of the Liver, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; FERRITIN; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; IRON; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TRANSFERRIN RECEPTOR 2; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

AMENORRHEA; ARTHRALGIA; ARTHRITIS; ARTICLE; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE DISEASE; FERRITIN BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HAIR LOSS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEART DISEASE; HEMOCHROMATOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HYPERFERRITINEMIA; HYPERPIGMENTATION; IRON OVERLOAD; LIBIDO DISORDER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOPOROSIS; PHLEBOTOMY; POLYMERASE CHAIN REACTION; POPULATION; PORPHYRIA CUTANEA TARDA; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; TISSUE INJURY; FEMALE; GENETICS; HOMOZYGOTE; MALE; MUTATION;

FEMALE; GENE FREQUENCY; GENETIC TESTING; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MUTATION; POLYMORPHISM, GENETIC; PREGNANCY;

EID: 77953120762     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.001     Document Type: Article

References (234)

1. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
2. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008) 924-926
3. Guyatt G.H., Oxman A.D., Kunz R., Vist G.E., Falck-Ytter Y., and Schunemann H.J. What is 'quality of evidence' and why is it important to clinicians?. BMJ 336 (2008) 995-998
4. Guyatt G.H., Oxman A.D., Kunz R., Jaeschke R., Helfand M., Liberati A., et al. Incorporating considerations of resources use into grading recommendations. BMJ 336 (2008) 1170-1173
5. Guyatt G.H., Oxman A.D., Kunz R., Falck-Ytter Y., Vist G.E., Liberati A., et al. Going from evidence to recommendations. BMJ 336 (2008) 1049-1051
6. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 328 (2004) 1490
7. Beckman L.E., Saha N., Spitsyn V., Van Landeghem G., and Beckman L. Ethnic differences in the HFE codon 282 (Cys/Tyr) polymorphism. Hum Hered 47 5 (1997) 263-267
8. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., and Robson K.J. Global prevalence of putative haemochromatosis mutations. J Med Genet 34 4 (1997) 275-278
9. Datz C., Lalloz M.R., Vogel W., Graziadei I., Hackl F., Vautier G., et al. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. J Hepatol 27 5 (1997) 773-779
10. Burt M.J., George P.M., Upton J.D., Collett J.A., Frampton C.M., Chapman T.M., et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 43 (1998) 830-836
11. Jouanolle A.M., Fergelot P., Raoul M.L., Gandon G., Roussey M., Deugnier Y., et al. Prevalence of the C282Y mutation in Brittany: penetrance of genetic hemochromatosis?. Ann Genet 41 4 (1998) 195-198
12. Merryweather-Clarke A.T., Simonsen H., Shearman J.D., Pointon J.J., Norgaard-Pedersen B., and Robson K.J. A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat 13 2 (1999) 154-159
13. Distante S., Berg J.P., Lande K., Haug E., and Bell H. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 34 (1999) 529-534
14. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., and Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341 (1999) 718-724
15. Marshall D.S., Linfert D.R., and Tsongalis G.J. Prevalence of the C282Y and H63D polymorphisms in a multi-ethnic control population. Int J Mol Med 4 4 (1999) 389-393
16. Beutler E., Felitti V., Gelbart T., and Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 133 5 (2000) 329-337
17. Steinberg K.K., Cogswell M.E., Chang J.C., Caudill S.P., McQuillan G.M., Bowman B.A., et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 285 17 (2001) 2216-2222
18. Andrikovics H., Kalmar L., Bors A., Fandl B., Petri I., Kalasz L., et al. Genotype screening for hereditary hemochromatosis among voluntary blood donors in Hungary. Blood Cells Mol Dis 27 1 (2001) 334-341
19. Pozzato G., Zorat F., Nascimben F., Gregorutti M., Comar C., Baracetti S., et al. Haemochromatosis gene mutations in a clustered Italian population: evidence of high prevalence in people of Celtic ancestry. Eur J Hum Genet 9 6 (2001) 445-451
20. Byrnes V., Ryan E., Barrett S., Kenny P., Mayne P., and Crowe J. Genetic hemochromatosis, a Celtic disease: is it now time for population screening?. Genet Test 5 2 (2001) 127-130
21. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
22. Guix P., Picornell A., Parera M., Galmes A., Obrador A., Ramon M.M., et al. Distribution of HFE C282Y and H63D mutations in the Balearic Islands (NE Spain). Clin Genet 61 1 (2002) 43-48
23. Deugnier Y., Jouanolle A.M., Chaperon J., Moirand R., Pithois C., Meyer J.F., et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 118 (2002) 1170-1178
24. Cimburova M., Putova I., Provaznikova H., and Horak J. Hereditary hemochromatosis: detection of C282Y and H63D mutations in HFE gene by means of guthrie cards in population of Czech Republic. Genet Epidemiol 23 3 (2002) 260-263
25. Van Aken M.O., De Craen A.J., Gussekloo J., Moghaddam P.H., Vandenbroucke J.P., Heijmans B.T., et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 32 10 (2002) 750-754
26. Phatak P.D., Ryan D.H., Cappuccio J., Oakes D., Braggins C., Provenzano K., et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 29 1 (2002) 41-47
27. Jones D.C., Young N.T., Pigott C., Fuggle S.V., Barnardo M.C., Marshall S.E., et al. Comprehensive hereditary hemochromatosis genotyping. Tissue Antigens 60 (2002) 481-488
28. Candore G., Mantovani V., Balistreri C.R., Lio D., Colonna-Romano G., Cerreta V., et al. Frequency of the HFE gene mutations in five Italian populations. Blood Cells Mol Dis 29 3 (2002) 267-273
29. Salvioni A., Mariani R., Oberkanins C., Moritz A., Mauri V., Pelucchi S., et al. Prevalence of C282Y and E168X HFE mutations in an Italian population of Northern European ancestry. Haematologica 88 3 (2003) 250-255
30. Papazoglou D., Exiara T., Speletas M., Panagopoulos I., and Maltezos E. Prevalence of hemochromatosis gene (HFE) mutations in Greece. Acta Haematol 109 3 (2003) 137-140
31. Sanchez M., Villa M., Ingelmo M., Sanz C., Bruguera M., Ascaso C., et al. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J Hepatol 38 6 (2003) 745-750
32. Mariani R., Salvioni A., Corengia C., Erba N., Lanzafame C., De Micheli V., et al. Prevalence of HFE mutations in upper Northern Italy: study of 1132 unrelated blood donors. Dig Liver Dis 35 7 (2003) 479-481
33. Altes A., Ruiz A., Barcelo M.J., Remacha A.F., Puig T., Maya A.J., et al. Prevalence of the C282Y, H63D, and S65C mutations of the HFE gene in 1146 newborns from a region of Northern Spain. Genet Test 8 4 (2004) 407-410
34. Adams P.C., Reboussin D.M., Barton J.C., McLaren C.E., Eckfeldt J.H., McLaren G.D., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005) 1769-1778
35. Barry E., Derhammer T., and Elsea S.H. Prevalence of three hereditary hemochromatosis mutant alleles in the Michigan Caucasian population. Community Genet 8 3 (2005) 173-179
36. Meier P., Schuff-Werner P., and Steiner M. Hemochromatosis gene HFE Cys282Tyr mutation analysis in a cohort of Northeast German hospitalized patients supports assumption of a North to South allele frequency gradient throughout Germany. Clin Lab 51 9-10 (2005) 539-543
37. Matas M., Guix P., Castro J.A., Parera M., Ramon M.M., Obrador A., et al. Prevalence of HFE C282Y and H63D in Jewish populations and clinical implications of H63D homozygosity. Clin Genet 69 2 (2006) 155-162
38. Hoppe C., Watson R.M., Long C.M., Lorey F., Robles L., Klitz W., et al. Prevalence of HFE mutations in California newborns. Pediatr Hematol Oncol 23 6 (2006) 507-516
39. Aranda N., Viteri F.E., Fernandez-Ballart J., Murphy M., and Arija V. Frequency of the hemochromatosis gene (HFE) 282C → Y, 63H → D, and 65S → C mutations in a general Mediterranean population from Tarragona, Spain. Ann Hematol 86 1 (2007) 17-21
40. Terzic R., Sehic A., Teran N., Terzic I., and Peterlin B. Frequency of HFE gene mutations C282Y and H63D in Bosnia and Herzegovina. Coll Antropol 30 3 (2006) 555-557
41. Floreani A., Rosa Rizzotto E., Basso D., Navaglia F., Zaninotto M., Petridis I., et al. An open population screening study for HFE gene major mutations proves the low prevalence of C282Y mutation in Central Italy. Aliment Pharmacol Ther 26 4 (2007) 577-586
42. Raszeja-Wyszomirska J., Kurzawski G., Suchy J., Zawada I., Lubinski J., and Milkiewicz P. Frequency of mutations related to hereditary haemochromatosis in northwestern Poland. J Appl Genet 49 1 (2008) 105-107
43. Jazwinska E.C., Cullen L.M., Busfield F., Pyper W.R., Webb S.I., Powell L.W., et al. Haemochromatosis and HLA-H. Nat Genet 14 3 (1996) 249-251
44. Jouanolle A.M., Gandon G., Jezequel P., Blayau M., Campion M.L., Yaouanq J., et al. Haemochromatosis and HLA-H. Nat Genet 14 3 (1996) 251-252
45. Beutler E., Gelbart T., West C., Lee P., Adams M., Blackstone R., et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 22 2 (1996) 187-194 discussion 194a-194b
46. Borot N., Roth M., Malfroy L., Demangel C., Vinel J.P., Pascal J.P., et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 45 5 (1997) 320-324
47. Carella M., D'Ambrosio L., Totaro A., Grifa A., Valentino M.A., Piperno A., et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 60 4 (1997) 828-832
48. Willis G., Jennings B.A., Goodman E., Fellows I.W., and Wimperis J.Z. A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England. Blood Cells Mol Dis 23 2 (1997) 288-291
49. The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997;41(6):841-4.
50. Press R.D., Flora K., Gross C., Rabkin J.M., and Corless C.L. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis. Am J Clin Pathol 109 5 (1998) 577-584
51. Cardoso E.M., Stal P., Hagen K., Cabeda J.M., Esin S., de Sousa M., et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 243 3 (1998) 203-208
52. Sanchez M., Bruguera M., Bosch J., Rodes J., Ballesta F., and Oliva R. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol 29 5 (1998) 725-728
53. Ryan E., O'Keane C., and Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 24 4 (1998) 428-432
54. Nielsen P., Carpinteiro S., Fischer R., Cabeda J.M., Porto G., and Gabbe E.E. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 103 3 (1998) 842-845
55. Murphy S., Curran M.D., McDougall N., Callender M.E., O'Brien C.J., and Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population - implications for haemochromatosis. Tissue Antigens 52 5 (1998) 484-488
56. Mura C., Raguenes O., and Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 93 (1999) 2502-2505
57. Brissot P., Moirand R., Jouanolle A.M., Guyader D., Le Gall J.Y., Deugnier Y., et al. A genotypic study of 217 unrelated probands diagnosed as 'genetic hemochromatosis' on 'classical' phenotypic criteria. J Hepatol 30 4 (1999) 588-593
58. Bacon B.R., Olynyk J.K., Brunt E.M., Britton R.S., and Wolff R.K. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 130 12 (1999) 953-962
59. Brandhagen D.J., Alvarez W., Therneau T.M., Kruckeberg K.E., Thibodeau S.N., Ludwig J., et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 31 (2000) 456-460
60. Rivard S.R., Mura C., Simard H., Simard R., Grimard D., Le Gac G., et al. Mutation analysis in the HFE gene in patients with hereditary haemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Br J Haematol 108 4 (2000) 854-858
61. Papanikolaou G., Politou M., Terpos E., Fourlemadis S., Sakellaropoulos N., and Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 26 2 (2000) 163-168
62. Guix P., Picornell A., Parera M., Tomas C., Muncunill J., Castro J.A., et al. Prevalence of the C282Y mutation for haemochromatosis on the Island of Majorca. Clin Genet 58 2 (2000) 123-128
63. Brandhagen D.J., Fairbanks V.F., Baldus W.P., Smith C.I., Kruckeberg K.E., Schaid D.J., et al. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol 95 10 (2000) 2910-2914
64. Sham R.L., Raubertas R.F., Braggins C., Cappuccio J., Gallagher M., and Phatak P.D. Asymptomatic hemochromatosis subjects: genotypic and phenotypic profiles. Blood 96 12 (2000) 3707-3711
65. Van Vlierberghe H., Messiaen L., Hautekeete M., De Paepe A., and Elewaut A. Prevalence of the Cys282Tyr and His63Asp mutation in Flemish patients with hereditary hemochromatosis. Acta Gastroenterol Belg 63 3 (2000) 250-253
66. Bell H., Berg J.P., Undlien D.E., Distante S., Raknerud N., Heier H.E., et al. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand J Gastroenterol 35 (2000) 1301-1307
67. Hellerbrand C., Bosserhoff A.K., Seegers S., Lingner G., Wrede C., Lock G., et al. Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol 36 11 (2001) 1211-1216
68. de Juan D., Reta A., Castiella A., Pozueta J., Prada A., and Cuadrado E. HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet 9 12 (2001) 961-964
69. De Marco F., Liguori R., Giardina M.G., D'Armiento M., Angelucci E., Lucariello A., et al. High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med 42 1 (2004) 17-24
70. Bauduer F., Scribans C., Degioanni A., Renoux M., and Dutour O. Distribution of the C282Y and H63D polymorphisms in hereditary hemochromatosis patients from the French Basque Country. Ann Hematol 84 2 (2005) 99-102
71. Cukjati M., Vaupotic T., Rupreht R., and Curin-Serbec V. Prevalence of H63D, S65C and C282Y hereditary hemochromatosis gene mutations in Slovenian population by an improved high-throughput genotyping assay. BMC Med Genet 8 (2007) 69
72. Walsh A., Dixon J.L., Ramm G.A., Hewett D.G., Lincoln D.J., Anderson G.J., et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 4 (2006) 1403-1410
73. Rossi E., Olynyk J.K., Cullen D.J., Papadopoulos G., Bulsara M., Summerville L., et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 46 (2000) 162-166
74. Lim E.M., Rossi E., De-Boer W.B., Reed W.D., and Jeffrey G.P. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int 24 (2004) 631-636
75. Cadet E., Capron D., Perez A.S., Crepin S.N., Arlot S., Ducroix J.P., et al. A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Med 253 (2003) 217-224
76. Swinkels D.W., Aalbers N., Elving L.D., Bleijenberg G., Swanink C.M., and van der Meer J.W. Primary haemochromatosis: a missed cause of chronic fatigue syndrome?. Neth J Med 60 (2002) 429-433
77. Vital Durand D., Francois S., Nove-Josserand R., Durupt S., Durieu I., Morel Y., et al. [Haemochromatosis screening in 120 patients complaining with persistent fatigue]. Rev Med Interne 25 (2004) 623-628
78. Willis G., Scott D.G., Jennings B.A., Smith K., Bukhari M., and Wimperis J.Z. HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford) 41 (2002) 176-179
79. Li J., Zhu Y., and Singal D.P. HFE gene mutations in patients with rheumatoid arthritis. J Rheumatol 27 (2000) 2074-2077
80. Rovetta G., Grignolo M.C., Buffrini L., and Monteforte P. Prevalence of C282Y mutation in patients with rheumatoid arthritis and spondylarthritis. Int J Tissue React 24 (2002) 105-109
81. Timms A.E., Sathananthan R., Bradbury L., Athanasou N.A., Wordsworth B.P., and Brown M.A. Genetic testing for haemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis 61 (2002) 745-747
82. Carroll G.J. Primary osteoarthritis in the ankle joint is associated with finger metacarpophalangeal osteoarthritis and the H63D mutation in the HFE gene: evidence for a hemochromatosis-like polyarticular osteoarthritis phenotype. J Clin Rheumatol 12 (2006) 109-113
83. Cauza E., Hanusch-Enserer U., Bischof M., Spak M., Kostner K., Tammaa A., et al. Increased C282Y heterozygosity in gestational diabetes. Fetal Diagn Ther 20 (2005) 349-354
84. Acton R.T., Barton J.C., Passmore L.V., Adams P.C., Speechley M.R., Dawkins F.W., et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 29 (2006) 2084-2089
85. Hahn J.U., Steiner M., Bochnig S., Schmidt H., Schuff-Werner P., and Kerner W. Evaluation of a diagnostic algorithm for hereditary hemochromatosis in 3500 patients with diabetes. Diabetes Care 29 (2006) 464-466
86. Frayling T., Ellard S., Grove J., Walker M., and Hattersley A.T. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 351 (1998) 1933-1934
87. Davis T.M., Beilby J., Davis W.A., Olynyk J.K., Jeffrey G.P., Rossi E., et al. Prevalence, characteristics and prognostic significance of HFE gene mutations in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 31 (2008) 1795-1801
88. Habeos I.G., Psyrogiannis A., Kyriazopoulou V., Psilopanagiotou A., Papavassiliou A.G., and Vagenakis A.G. The role of Hemochromatosis C282Y and H63D mutations in the development of type 2 diabetes mellitus in Greece. Hormones (Athens) 2 (2003) 55-60
89. Qi L., Meigs J., Manson J.E., Ma J., Hunter D., Rifai N., et al. HFE genetic variability, body iron stores, and the risk of type 2 diabetes in U.S. women. Diabetes 54 (2005) 3567-3572
90. Halsall D.J., McFarlane I., Luan J., Cox T.M., and Wareham N.J. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case-control study. Hum Mol Genet 12 (2003) 1361-1365
91. Fernandez-Real J.M., Vendrell J., Baiget M., Gimferrer E., and Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 22 (1999) 525-526
92. Braun J., Donner H., Plock K., Rau H., Usadel K.H., and Badenhoop K. Hereditary haemochromatosis mutations (HFE) in patients with Type II diabetes mellitus. Diabetologia 41 (1998) 983-984
93. Malecki M.T., Klupa T., Walus M., Czogala W., Greenlaw P., and Sieradzki J. A search for association between hereditary hemochromatosis HFE gene mutations and type 2 diabetes mellitus in a Polish population. Med Sci Mon Int Med J Exp Clin Res 9 (2003) BR91-BR95
94. Sampson M.J., Williams T., Heyburn P.J., Greenwood R.H., Temple R.C., Wimperis J.Z., et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 135 (2000) 170-173
95. Njajou O.T., Alizadeh B.Z., Vaessen N., Vergeer J., Houwing-Duistermaat J., Hofman A., et al. The role of hemochromatosis C282Y and H63D gene mutations in type 2 diabetes: findings from the Rotterdam Study and meta-analysis. Diabetes Care 25 (2002) 2112-2113
96. Peterlin B., Globocnik Petrovic M., Makuc J., Hawlina M., and Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. J Hum Genet 48 (2003) 646-649
97. Ellervik C., Mandrup-Poulsen T., Nordestgaard B.G., Larsen L.E., Appleyard M., Frandsen M., et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 358 (2001) 1405-1409
98. Poullis A., Moodie S.J., Ang L., Finlayson C.J., Levin G.E., and Maxwell J.D. Routine transferrin saturation measurement in liver clinic patients increases detection of hereditary haemochromatosis. Ann Clin Biochem 40 (2003) 521-527
99. Poullis A., Moodie S.J., and Maxwell J.D. Clinical haemochromatosis in HFE mutation carriers. Lancet 360 (2002) 411-412
100. Nichols L., Dickson G., Phan P.G., and Kant J.A. Iron binding saturation and genotypic testing for hereditary hemochromatosis in patients with liver disease. Am J Clin Pathol 125 (2006) 236-240
101. Willis G., Bardsley V., Fellows I.W., Lonsdale R., Wimperis J.Z., and Jennings B.A. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol 1 (2005) 5-17
102. Cauza E., Peck-Radosavljevic M., Ulrich-Pur H., Datz C., Gschwantler M., Schoniger-Hekele M., et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 98 (2003) 442-447
103. Hellerbrand C., Poppl A., Hartmann A., Scholmerich J., and Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 1 (2003) 279-284
104. Boige V., Castera L., de Roux N., Ganne-Carrie N., Ducot B., Pelletier G., et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 52 (2003) 1178-1181
105. Lauret E., Rodriguez M., Gonzalez S., Linares A., Lopez-Vazquez A., Martinez-Borra J., et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 97 (2002) 1016-1021
106. Pirisi M., Toniutto P., Uzzau A., Fabris C., Avellini C., Scott C., et al. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 89 (2000) 297-302
107. Fargion S., Stazi M.A., Fracanzani A.L., Mattioli M., Sampietro M., Tavazzi D., et al. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 27 (2001) 505-511
108. Bonkovsky H.L., Poh Fitzpatrick M., Pimstone N., Obando J., Di Bisceglie A., Tattrie C., et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology (Baltimore, MD) 27 (1998) 1661-1669
109. Chiaverini C., Halimi G., Ouzan D., Halfon P., Ortonne J.P., and Lacour J.P. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology (Basel, Switzerland) 206 (2003) 212-216
110. Cribier B., Chiaverini C., Dali Youcef N., Schmitt M., Grima M., Hirth C., et al. Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case-control study. Dermatology (Basel, Switzerland) 218 (2009) 15-21
111. Egger N.G., Goeger D.E., Payne D.A., Miskovsky E.P., Weinman S.A., and Anderson K.E. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 47 (2002) 419-426
112. Frank J., Poblete Gutierrez P., Weiskirchen R., Gressner O., Merk H.F., and Lammert F. Hemochromatosis gene sequence deviations in German patients with porphyria cutanea tarda. Physiol Res 55 (2006) S75-S83
113. Gonzalez Hevilla M., de Salamanca R.E., Morales P., Martinez Laso J., Fontanellas A., Castro M.J., et al. Human leukocyte antigen haplotypes and HFE mutations in Spanish hereditary hemochromatosis and sporadic porphyria cutanea tarda. J Gastroenterol Hepatol 20 (2005) 456-462
114. Hift R.J., Corrigall A.V., Hancock V., Kannemeyer J., Kirsch R.E., and Meissner P.N. Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol (Noisy le Grand, France) 48 (2002) 853-859
115. Kratka K., Dostalikova Cimburova M., Michalikova H., Stransky J., Vranova J., and Horak J. High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic. Br J Dermatol 159 (2008) 585-590
116. Lamoril J., Andant C., Gouya L., Malonova E., Grandchamp B., Martasek P., et al. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol (Noisy-le-grand) 48 (2002) 33-41
117. Martinelli A.L., Zago M.A., Roselino A.M., Filho A.B., Villanova M.G., Secaf M., et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 95 (2000) 3516-3521
118. Mehrany K., Drage L.A., Brandhagen D.J., and Pittelkow M.R. Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol 51 (2004) 205-211
119. Nagy Z., Koszo F., Par A., Emri G., Horkay I., Horanyi M., et al. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int 24 (2004) 16-20
120. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., and Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349 (1997) 321-323
121. Stolzel U., Kostler E., Schuppan D., Richter M., Wollina U., Doss M.O., et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 139 (2003) 309-313
122. Stuart K.A., Busfield F., Jazwinska E.C., Gibson P., Butterworth L.A., Cooksley W.G., et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 28 (1998) 404-409
123. Tannapfel A., Stolzel U., Kostler E., Melz S., Richter M., Keim V., et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 439 (2001) 1-5
124. Toll A., Celis R., Ozalla M.D., Bruguera M., Herrero C., and Ercilla M.G. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol 20 (2006) 1201-1206
125. Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A., Corbetta N., et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology (Baltimore, MD) 27 (1998) 181-184
126. Ellervik C., Birgens H., Tybjaerg Hansen A., and Nordestgaard B.G. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology (Baltimore, MD) 46 (2007) 1071-1080
127. McDonnell S.M., Hover A., Gloe D., Ou C.Y., Cogswell M.E., and Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 107 1 (1999) 30-37
128. Delatycki M.B., Allen K.J., Nisselle A.E., Collins V., Metcalfe S., du Sart D., et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 366 9482 (2005) 314-316
129. Adams P.C., Kertesz A.E., McLaren C.E., Barr R., Bamford A., and Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5211 voluntary blood donors. Hepatology 31 (2000) 1160-1164
130. Barton J.C., Acton R.T., Lovato L., Speechley M.R., McLaren C.E., Harris E.L., et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study. Clin Genet 69 (2006) 48-57
131. Asberg A., Hveem K., Thorstensen K., Ellekjter E., Kannelonning K., Fjosne U., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 36 (2001) 1108-1115
132. Gordeuk V.R., Reboussin D.M., McLaren C.E., Barton J.C., Acton R.T., McLaren G.D., et al. Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol 83 8 (2008) 618-626
133. Waalen J., Felitti V.J., Gelbart T., and Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 111 (2008) 3373-3376
134. Bax L., Yu L.M., Ikeda N., Tsuruta H., and Moons K.G. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 6 (2006) 50
135. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KGM. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7., 2009.
136. Distante S., Berg J.P., Lande K., Haug E., and Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47 4 (2000) 575-579
137. Bulaj Z.J., Ajioka R.S., Phillips J.D., LaSalle B.A., Jorde L.B., Griffen L.M., et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 343 21 (2000) 1529-1535
138. Barton J.C., Rothenberg B.E., Bertoli L.F., and Acton R.T. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1 3 (1999) 89-93
139. Waalen J., Felitti V., Gelbart T., Ho N.J., and Beutler E. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc 77 6 (2002) 522-530
140. Olynyk J.K., Hagan S.E., Cullen D.J., Beilby J., and Whittall D.E. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 79 (2004) 309-313
141. Andersen R.V., Tybjaerg-Hansen A., Appleyard M., Birgens H., and Nordestgaard B.G. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 (2004) 2914-2919
142. Gleeson F., Ryan E., Barrett S., and Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol 16 (2004) 859-863
143. Rossi E., Kuek C., Beilby J.P., Jeffrey G.P., Devine A., and Prince R.L. Expression of the HFE hemochromatosis gene in a community-based population of elderly women. J Gastroenterol Hepatol 19 10 (2004) 1150-1154
144. Powell L.W., Dixon J.L., Ramm G.A., Purdie D.M., Lincoln D.J., Anderson G.J., et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166 (2006) 294-301
145. Asberg A., Hveem K., Kannelonning K., and Irgens W.O. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand J Gastroenterol 42 (2007) 1073-1077
146. Allen K.J., Gurrin L.C., Constantine C.C., Osborne N.J., Delatycki M.B., Nicoll A.J., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358 (2008) 221-230
147. Whitlock E.P., Garlitz B.A., Harris E.L., Beil T.L., and Smith P.R. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 145 (2006) 209-223
148. Feder J.N. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res 20 2 (1999) 175-185
149. Jazwinska E.C., and Powell L.W. Hemochromatosis and 'HLA-H': definite!. Hepatology 25 2 (1997) 495-496
150. Koeken A., Cobbaert C., Quint W., and van Doorn L.J. Genotyping of hemochromatosis-associated mutations in the HFE gene by PCR-RFLP and a novel reverse hybridization method. Clin Chem Lab Med FESCC 40 2 (2002) 122-125
151. Cunat S., Giansily Blaizot M., Bismuth M., Blanc F., Dereure O., Larrey D., et al. Global sequencing approach for characterizing the molecular background of hereditary iron disorders. Clin Chem 53 12 (2007) 2060-2069
152. Cukjati M., Koren S., Curin Serbec V., Vidan-Jeras B., and Rupreht R. A novel homozygous frameshift deletion c.471del of HFE associated with hemochromatosis. Clin Genet 71 4 (2007) 350-353
153. Steiner M., Ocran K., Genschel J., Meier P., Gerl H., Ventz M., et al. A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology 122 (2002) 789-795
154. Barton J.C., Sawada Hirai R., Rothenberg B.E., and Acton R.T. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis 25 (1999) 147-155
155. de Kok J.B., Wiegerinck E.T., Giesendorf B.A., and Swinkels D.W. Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum Mutat 19 5 (2002) 554-559
156. Behrens M., and Lange R. A highly reproducible and economically competitive SNP analysis of several well characterized human mutations. Clin Lab 50 5-6 (2004) 305-316
157. Alsmadi O.A., Al Kayal F., Al Hamed M., and Meyer B.F. Frequency of common HFE variants in the Saudi population: a high throughput molecular beacon-based study. BMC Med Genet 7 (2006) 43
158. Castley A., Higgins M., Ivey J., Mamotte C., Sayer D.C., and Christiansen F.T. Clinical applications of whole-blood PCR with real-time instrumentation. Clin Chem 51 11 (2005) 2025-2030
159. Walburger D.K., Afonina I.A., and Wydro R. An improved real time PCR method for simultaneous detection of C282Y and H63D mutations in the HFE gene associated with hereditary hemochromatosis. Mutat Res 432 3-4 (2001) 69-78
160. Cheng J., Zhang Y., and Li Q. Real-time PCR genotyping using displacing probes. Nucleic Acids Res 32 7 (2004) e61
161. Bach V., Barcelo M.J., Altes A., Remacha A., Felez J., and Baiget M. Genotyping the HFE gene by melting point analysis with the LightCycler system: Pros and cons. Blood Cells Mol Dis 36 2 (2006) 288-291
162. Moyses C.B., Moreira E.S., Asprino P.F., Guimaraes G.S., and Alberto F.L. Simultaneous detection of the C282Y, H63D and S65C mutations in the hemochromatosis gene using quenched-FRET real-time PCR. Braz J Med Biol Res [Rev Bras Pesq Med Biol, Sociedade Brasileira de Biofisica] 41 10 (2008) 833-838
163. Biasiotto G., Belloli S., Ruggeri G., Zanella I., Gerardi G., Corrado M., et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 49 (2003) 1981-1988
164. Smillie D. A PCR-SSP method for detecting the Cys282Tyr mutation in the HFE gene associated with hereditary haemochromatosis. Mol Pathol 50 5 (1997) 275-276
165. Smillie D. A PCR-SSP method for detecting the His63Asp mutation in the HFE gene associated with hereditary haemochromatosis. Mol Pathol 51 4 (1998) 232-233
166. Steffensen R., Varming K., and Jersild C. Determination of gene frequencies for two common haemochromatosis mutations in the Danish population by a novel polymerase chain reaction with sequence-specific primers. Tissue Antigens 52 3 (1998) 230-235
167. Wenz H.M., Baumhueter S., Ramachandra S., and Worwood M. A rapid automated SSCP multiplex capillary electrophoresis protocol that detects the two common mutations implicated in hereditary hemochromatosis (HH). Hum Genet 104 1 (1999) 29-35
168. Guttridge M.G., Carter K., Worwood M., and Darke C. Population screening for hemochromatosis by PCR using sequence-specific primers. Genet Test 4 2 (2000) 111-114
169. Guttridge M.G., Thompson J., Worwood M., and Darke C. Rapid detection of genetic mutations associated with haemochromatosis. Vox Sang 75 3 (1998) 253-256
170. Kaur G., Rapthap C.C., Xavier M., Saxena R., Choudhary V.P., Reuben S.K., et al. Distribution of C282Y and H63D mutations in the HFE gene in healthy Asian Indians and patients with thalassaemia major. Natl Med J India 16 6 (2003) 309-310
171. Turner M.S., Penning S., Sharp A., Hyland V.J., Harris R., Morris C.P., et al. Solid-phase amplification for detection of C282y and H63D hemochromatosis (HFE) gene mutations. Clin Chem 47 8 (2001) 1384-1389
172. Bosserhoff A.K., Seegers S., Hellerbrand C., Scholmerich J., and Buttner R. Rapid genetic screening for hemochromatosis using automated SSCP-based capillary electrophoresis (SSCP-CE). Biotechniques 26 6 (1999) 1106-1110
173. Simonsen K., Dissing J., Rudbeck L., and Schwartz M. Rapid and simple determination of hereditary haemochromatosis mutations by multiplex PCR-SSCP: detection of a new polymorphic mutation. Ann Hum Genet 63 Pt 3 (1999) 193-197
174. Kim S., Edwards J.R., Deng L., Chung W., and Ju J. Solid phase capturable dideoxynucleotides for multiplex genotyping using mass spectrometry. Nucleic Acids Research 30 16 (2002) e85
175. Bernacki S.H., Farkas D.H., Shi W., Chan V., Liu Y., Beck J.C., et al. Bioelectronic sensor technology for detection of cystic fibrosis and hereditary hemochromatosis mutations. Arch Pathol Lab Med 127 12 (2003) 1565-1572
176. Footz T., Somerville M.J., Tomaszewski R., Elyas B., and Backhouse C.J. Integration of combined heteroduplex/restriction fragment length polymorphism analysis on an electrophoresis microchip for the detection of hereditary haemochromatosis. Analyst 129 1 (2004) 25-31
177. Bosserhoff A.K., Buettner R., and Hellerbrand C. Use of capillary electrophoresis for high throughput screening in biomedical applications. A minireview. Comb Chem High Throughput Screen 3 6 (2000) 455-466
178. Devaney J.M., Pettit E.L., Kaler S.G., Vallone P.M., Butler J.M., and Marino M.A. Genotyping of two mutations in the HFE gene using single-base extension and high-performance liquid chromatography. Anal Chem 73 3 (2001) 620-624
179. Lubin I.M., Yamada N.A., Stansel R.M., Pace R.G., Rohlfs E.M., and Silverman L.M. HFE genotyping using multiplex allele-specific polymerase chain reaction and capillary electrophoresis. Arch Pathol Lab Med 123 12 (1999) 1177-1181
180. Kotze M.J., de Villiers J.N., Bouwens C.S., Warnich L., Zaahl M.G., van der Merwe S., et al. Molecular diagnosis of hereditary hemochromatosis: application of a newly-developed reverse-hybridization assay in the South African population. Clin Genet 65 4 (2004) 317-321
181. Oberkanins C., Moritz A., de Villiers J.N., Kotze M.J., and Kury F. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 4 (2000) 121-124
182. Rivers C.A., Barton J.C., and Acton R.T. A rapid PCR-SSP assay for the hemochromatosis-associated Tyr250Stop mutation in the TFR2 gene. Genet Test 5 2 (2001) 131-134
183. Somerville M.J., Sprysak K.A., Hicks M., Elyas B.G., and Vicen-Wyhony L. An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis. Am J Hum Genet 65 (1999) 924-926
184. Klaassen C.H., van Aarssen Y.A., and van der Stappen J.W. Improved real-time detection of the H63D and S65C mutations associated with hereditary hemochromatosis using a SimpleProbe assay format. Clin Chem Lab Med 46 (2008) 985-986
185. Schranz M., Talasz H., Graziadei I., Winder T., Sergi C., Bogner K., et al. Diagnosis of hepatic iron overload: a family study illustrating pitfalls in diagnosing hemochromatosis. Diagn Mol Pathol 18 (2009) 53-60
186. Sebastiani G., Wallace D.F., Davies S.E., Kulhalli V., Walker A.P., and Dooley J.S. Fatty liver in H63D homozygotes with hyperferritinemia. World J Gastroenterol 12 (2006) 1788-1792
187. Jackson H.A., Carter K., Darke C., Guttridge M.G., Ravine D., Hutton R.D., et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114 (2001) 474-484
188. de Villiers J.N., Hillermann R., Loubser L., and Kotze M.J. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Genet 8 (1999) 1517-1522
189. Bradbury R., Fagan E., and Payne S.J. Two novel polymorphisms (E277K and V212V) in the haemochromatosis gene HFE. Hum Mutat 15 (2000) 120
190. Floreani A., Navaglia F., Basso D., Zambon C.F., Basso G., Germano G., et al. Intron 2 [IVS2, T-C +4] HFE gene mutation associated with S65C causes alternative RNA splicing and is responsible for iron overload. Hepatol Res 33 (2005) 57-60
191. Piperno A., Arosio C., Fossati L., Vigano M., Trombini P., Vergani A., et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 119 (2000) 441-445
192. Wallace D.F., Dooley J.S., and Walker A.P. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 116 (1999) 1409-1412
193. Gochee P.A., Powell L.W., Cullen D.J., Du Sart D., Rossi E., and Olynyk J.K. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122 (2002) 646-651
194. Wallace D.F., Walker A.P., Pietrangelo A., Clare M., Bomford A.B., Dixon J.L., et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol 36 (2002) 474-479
195. Aguilar Martinez P., Biron C., Blanc F., Masmejean C., Jeanjean P., Michel H., et al. Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease?. Blood Cells Mol Dis 23 (1997) 269-276
196. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363 (2004) 357-362
197. St Pierre T.G., Clark P.R., Chua-Anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
198. Ernst O., Sergent G., Bonvarlet P., Canva-Delcambre V., Paris J.C., and L'Hermine C. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol 168 (1997) 1205-1208
199. Brittenham G.M., Farrell D.E., Harris J.W., Feldman E.S., Danish E.H., Muir W.A., et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 307 (1982) 1671-1675
200. Nielsen P., Engelhardt R., Duerken M., Janka G.E., and Fischer R. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 23 (2000) 257-258
201. Fischer R., Piga A., Harmatz P., and Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci 1054 (2005) 350-357
202. Guyader D., Jacquelinet C., Moirand R., Turlin B., Mendler M.H., Chaperon J., et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115 (1998) 929-936
203. Morrison E.D., Brandhagen D.J., Phatak P.D., Barton J.C., Krawitt E.L., El-Serag H.B., et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 138 (2003) 627-633
204. Crawford D.H., Murphy T.L., Ramm L.E., Fletcher L.M., Clouston A.D., Anderson G.J., et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 49 (2009) 418-425
205. Adhoute X., Foucher J., Laharie D., Terrebonne E., Vergniol J., Castera L., et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 32 (2008) 180-187
206. El Serag H.B., Inadomi J.M., and Kowdley K.V. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 132 (2000) 261-269
207. Houglum K., Ramm G.A., Crawford D.H., Witztum J.L., Powell L.W., and Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology 26 (1997) 605-610
208. Bassett M.L., Halliday J.W., and Powell L.W. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6 (1986) 24-29
209. Le Lan C., Loreal O., Cohen T., Ropert M., Glickstein H., Laine F., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 105 (2005) 4527-4531
210. Bomford A., and Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 45 (1976) 611-623
211. Milman N., Pedersen P., a Steig T., Byg K.E., Graudal N., and Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 80 (2001) 737-744
212. Falize L., Guillygomarc'h A., Perrin M., Laine F., Guyader D., Brissot P., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 (2006) 472-477
213. Powell L.W., and Kerr J.F. Reversal of 'cirrhosis' in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 19 (1970) 54-57
214. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., and Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
215. Fracanzani A.L., Fargion S., Romano R., Conte D., Piperno A., D'Alba R., et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 22 (1995) 1127-1131
216. Adams P.C. Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis. Am J Hematol 58 (1998) 16-19
217. Hicken B.L., Tucker D.C., and Barton J.C. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 98 (2003) 2072-2077
218. Adams P.C., Kertesz A.E., and Valberg L.S. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol 16 (1993) 207-210
219. Hutchinson C., Geissler C.A., Powell J.J., and Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56 (2007) 1291-1295
220. Kaltwasser J.P., Werner E., Schalk K., Hansen C., Gottschalk R., and Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43 (1998) 699-704
221. Milward E.A., Baines S.K., Knuiman M.W., Bartholomew H.C., Divitini M.L., Ravine D.G., et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 83 (2008) 543-549
222. Nienhuis A.W. Vitamin C and iron. N Engl J Med 304 (1981) 170-171
223. Schofield R.S., Aranda Jr. J.M., Hill J.A., and Streiff R. Cardiac transplantation in a patient with hereditary hemochromatosis: role of adjunctive phlebotomy and erythropoietin. J Heart Lung Transplant 20 (2001) 696-698
224. Barton J.C., Grindon A.J., Barton N.H., and Bertoli L.F. Hemochromatosis probands as blood donors. Transfusion 39 (1999) 578-585
225. Fletcher L.M., Dixon J.L., Purdie D.M., Powell L.W., and Crawford D.H. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122 (2002) 281-289
226. Harrison-Findik D.D., Klein E., Crist C., Evans J., Timchenko N., and Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46 (2007) 1979-1985
227. Chapman R.W., Morgan M.Y., Boss A.M., and Sherlock S. Acute and chronic effects of alcohol on iron absorption. Dig Dis Sci 28 (1983) 321-327
228. Ioannou G.N., Dominitz J.A., Weiss N.S., Heagerty P.J., and Kowdley K.V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology 126 (2004) 1293-1301
229. Ioannou G.N., Weiss N.S., and Kowdley K.V. Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. Clin Gastroenterol Hepatol 5 (2007) 624-629
230. Barton J.C., McDonnell S.M., Adams P.C., Brissot P., Powell L.W., Edwards C.Q., et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 129 (1998) 932-939
231. Kowdley K.V., Brandhagen D.J., Gish R.G., Bass N.M., Weinstein J., Schilsky M.L., et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 129 (2005) 494-503
232. Yu L., and Ioannou G.N. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 133 (2007) 489-495
233. Edwards C.Q., Kelly T.M., Ellwein G., and Kushner J.P. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 143 (1983) 1890-1893
234. Guggenbuhl P., Deugnier Y., Boisdet J.F., Rolland Y., Perdriger A., Pawlotsky Y., et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16 (2005) 1809-1814